Evaluation of the Immunogenicity and Efficacy of HIV-1 Clade A BG505 SOSIP.664 Env Glycoprotein Trimer Vaccine Administered with TLR Agonist or Alum Adjuvants

HIV-1 A 进化枝 BG505 SOSIP.664 Env 糖蛋白三聚体疫苗与 TLR 激动剂或明矾佐剂联合给药的免疫原性和功效评估

• 批准号: 10650275
• 负责人: MARIA GRAZIA FERRARI
• 金额: $ 76.53万
• 依托单位: BIOQUAL, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-05-16 至 2024-05-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10650275
• 关键词: AIDS Vaccines; AIDS prevention; Adjuvant; Agonist; Breeding; Development; Evaluation; Formulation; HIV vaccine; HIV-1; Housing; Immune response; Maintenance; Modality; Modeling; Mucosal Immune Responses; National Institute of Allergy and Infectious Disease; Prevention Research; Prevention strategy; Research Personnel; Resources; Risk; Testing; United States National Institutes of Health; Vaccine Research; Vaccines; Virus; Virus Diseases; adaptive immune response; aluminum sulfate; clinical efficacy; env Glycoproteins; evaluation/testing; flexibility; immunogenicity; nonhuman primate; preclinical evaluation; preclinical study; prevent; programs; research clinical testing; vaccine efficacy; vaccine evaluation

The development of effective HIV vaccines and other prevention strategies relies on the use of nonhuman primates (NHPs) in preclinical studies. To meet this need, the Simian Vaccine Evaluation Units (SVEUs) provide NHP resources that primarily support preclinical evaluation of AIDS vaccines and prevention modalities. The SVEU program will provide NIAID the ability to evaluate candidate AIDS vaccines using NHP models in which thorough evaluations of systemic and mucosal immune responses can be conducted, vaccine efficacy can easily be tested, correlates of reduced risk of virus acquisition can be identified, and approaches to enhance immunogenicity and efficacy of clinical vaccines can be conducted. The SVEUs will provide a responsive, flexible vaccine resource that is available to NIH-supported researchers and can support all stages of AIDS vaccine research, from preclinical evaluation or clinical testing of candidate AIDS vaccines, with the objective of identifying a vaccine that will generate immune responses able to prevent or control viral infection. The scope of the SVEUs includes housing and maintenance of NHPs, the conduct of studies supporting AIDS prevention research, with an emphasis on AIDS vaccines, support of a NHP breeding colony, and general administration and management of these activities.

有效的 HIV 疫苗和其他预防策略的开发依赖于在临床前研究中使用非人类灵长类动物 (NHP)。为了满足这一需求，猿猴疫苗评估单位 (SVEU) 提供 NHP 资源，主要支持艾滋病疫苗和预防方式的临床前评估。 SVEU 计划将为 NIAID 提供使用 NHP 模型评估候选艾滋病疫苗的能力，在该模型中可以对系统和粘膜免疫反应进行彻底评估，可以轻松测试疫苗功效，可以确定病毒感染风险降低的相关性，并确定方法增强临床疫苗的免疫原性和功效。 SVEU 将提供响应迅速、灵活的疫苗资源，可供 NIH 支持的研究人员使用，并可支持艾滋病疫苗研究的所有阶段，从候选艾滋病疫苗的临床前评估或临床测试，目的是确定一种能够产生免疫的疫苗。能够预防或控制病毒感染的反应。 SVEU 的范围包括 NHP 的住房和维护、开展支持艾滋病预防研究（重点是艾滋病疫苗）的研究、支持 NHP 繁殖群体以及这些活动的一般管理和管理。